ReviewBiomicrofluidics2024
Digital microfluidics methods for nucleic acid detection: A mini review.
Review in Biomicrofluidics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Biodetection of Mycobacterium tuberculosis: nano-biosensors in detection; from principles to recent progresses.Journal of biological engineering · 2026Review
- Paper-Based Microfluidic Chips for At-Home Point-of-Care Nucleic Acid Testing: Applications and Challenges.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many serious infectious diseases have occurred throughout human history. Rapid and accurate detection as well as the isolation of infected individuals, through nucleic acid testing, are effective means of containing the spread of these viruses. However, traditional nucleic acid testing methods rely on complex machines and specialized personnel, making it difficult to achieve large-scale, high-throughput, and rapid detection. In recent years, digital microfluidics has emerged as a promising technology that integrates various fields, including electrokinetics, acoustics, optics, magnetism, and mechanics. By leveraging the advantages of these different technologies, digital microfluidic chips offer several benefits, such as high detection throughput, integration of multiple functions, low reagent consumption, and portability. This rapid and efficient testing is crucial in the timely detection and isolation of infected individuals to prevent the virus spread. Another advantage is the low reagent consumption of digital microfluidic chips. Compared to traditional methods, these chips require smaller volumes of reagents, resulting in cost savings and reduced waste. Furthermore, digital microfluidic chips are portable and can be easily integrated into point-of-care testing devices. This enables testing to be conducted in remote or resource-limited areas, where access to complex laboratory equipment may be limited. Onsite testing reduces the time and cost associated with sample transportation. In conclusion, bioassay technologies based on digital microfluidic principles have the potential to significantly improve infectious disease detection and control. By enabling rapid, high-throughput, and portable testing, these technologies enhance our ability to contain the spread of infectious diseases and effectively manage public health outbreaks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.